Search Results - "ANTHONY TOLCHER" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

by Munster, Pamela, Eckhardt, S. Gail, Patnaik, Amita, Shields, Anthony F., Tolcher, Anthony W., Davis, S. Lindsey, Heymach, John V., Xu, Lu, Kapoun, Ann M., Faoro, Leonardo, Dupont, Jakob, Ferrarotto, Renata
Published in Molecular cancer therapeutics (01.12.2015)

Get full text

Journal Article

Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH)

Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH)

by Vis, Daniel J., Lewin, Jeremy, Siu, Lillian, Liao, Rachel, Zenklusen, Jean Claude, Calvo, Fabien, Szepessy, Edit, Vivancos, Ana, Wirta, Valtteri, Madhavan, Subha, Park, Keunchil, Tan, Daniel, Laskin, Janessa, Brammer, Melissa, Dias-Neto, Emmanuel, Tolcher, Anthony, Hudson, Thomas J., Sawyers, Charles, Lawler, Mark, Voest, Emile E.
Published in Cancer research (Chicago, Ill.) (15.07.2016)

Get full text

Journal Article

Abstract LB-201: Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors

Abstract LB-201: Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors

by Patnaik, Amita, Tolcher, Anthony, Beeram, Muralidhar, Nemunaitis, John, Weiss, Glen, Nichols, Gwen, Middleton, Steven, Sarapa, Nenad, Beryozkina, Anna, Zhi, Jianguo
Published in Cancer research (Chicago, Ill.) (15.04.2013)

Get full text

Journal Article

Abstract 31: A population pharmacokinetic-pharmacodynamic (POP-PK/PD) modelling of EZN-3042 administered with or without docetaxel in patients with advanced solid tumors or lymphoma

Abstract 31: A population pharmacokinetic-pharmacodynamic (POP-PK/PD) modelling of EZN-3042 administered with or without docetaxel in patients with advanced solid tumors or lymphoma

by Baudry, E, Rezai, Keyvan, Urien, Saik, Tolcher, Anthony, Patnaik, Amita, Papadopoulos, Kyriakos P., Agnew, James, Buchbinder, Aby, Lokiec, Francois
Published in Cancer research (Chicago, Ill.) (15.04.2013)

Get full text

Journal Article

Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors

Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors

by Tolcher, Anthony W., Papadopoulos, Kyriakos P., Patnaik, Amita, Rasco, Drew Warren, Martinez, Dorothy, Wood, Debra L, Fielman, Barbara, Sharma, Manish, Janisch, Linda A., Brown, Bob D, Bhargava, Pankaj, Ratain, Mark J.
Published in Journal of clinical oncology (20.05.2015)

Get full text

Journal Article

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

by Patnaik, Amita, Tolcher, Anthony, Papadopoulos, Kyriakos P., Beeram, Murali, Rasco, Drew, Werner, Theresa L., Bauman, John W., Scheuber, Anita, Cox, Donna S., Patel, Bela R., Zhou, YanYan, Hamid, Mohammed, Schramek, Daniel, Sharma, Sunil
Published in Cancer chemotherapy and pharmacology (01.09.2016)

Get full text

Journal Article

Routine molecular profiling of solid tumors in a community cancer center's genomic pathology laboratory

Routine molecular profiling of solid tumors in a community cancer center's genomic pathology laboratory

by Gunn, Shelly, Reveles, Xavier, Smith, Lon S., Rodriguez, Gladys Isabel, Patnaik, Amita, Beeram, Muralidhar, Papadopoulos, Kyriakos P., Rasco, Drew Warren, Tolcher, Anthony W.
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors

A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors

by Tolcher, Anthony W., Chugh, Rashmi, Chambers, Glenda, Thorpe, Villette, Dupont, Jakob, Hill, Dawn, Xu, Lu, Kapoun, Ann, Smith, David C.
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation

by Stroh, Mark, Talaty, Jennifer, Sandhu, Punam, McCrea, Jacqueline, Patnaik, Amita, Tolcher, Anthony, Palcza, John, Orford, Keith, Breidinger, Sheila, Narasimhan, Narayana, Panebianco, Deborah, Lush, Richard, Papadopoulos, Kyriakos P, Wagner, John A, Trucksis, Michele, Agrawal, Nancy
Published in Journal of clinical pharmacology (01.11.2014)

Get more information

Journal Article

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion

by Tolcher, Anthony, Julian, Thomas, Qureshi, Anila
Published in Blood (16.11.2007)

Get full text

Journal Article

Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results

Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results

by Capelan, Marta, Kumar, Prasana, Tolcher, Anthony W., Zivi, Andrea, Desai, Madhuri, Papadopoulos, Kyriakos P., Senaldi, Giorgio, Patnaik, Amita, Banerji, Udai, Rasco, Drew D.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A111: Effects of unconjugated antibody pretreatment to reduce ADC-related toxicity: Preclinical effects of trastuzumab on T-DM1 activity in low passage breast PDX models

Abstract A111: Effects of unconjugated antibody pretreatment to reduce ADC-related toxicity: Preclinical effects of trastuzumab on T-DM1 activity in low passage breast PDX models

by Chavez, Roger, Wick, Michael J., Vaught, Teresa L., Tolcher, Anthony W., Tolcher, Meredith P., Diaz, Armando, Rasco, Drew, Patnaik, Amita, Rodriguez, Gladys, Smith, Lon, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870)

Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870)

by Boni, Valentina, Rixe, Olivier, Rasco, Drew, Gomez-Roca, Carlos, Calvo, Emiliano, Morris, John C., Tolcher, Anthony W., Assadourian, Sylvie, Guillemin, Helene, Delord, Jean-Pierre
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A106: Utilization of low passage adenoid cystic carcinoma (ACC) models to identify novel therapies

Abstract A106: Utilization of low passage adenoid cystic carcinoma (ACC) models to identify novel therapies

by Meade, Justin, Wick, Michael J., Vaught, Teresa L., Carlile, Jennifer, Tolcher, Anthony W., Rasco, Drew, Patnaik, Amita, Kaufman, Jeffrey, Moskaluk, Chris, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors

Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors

by Smith, David C., Rosen, Lee, Wang, Min, Zhang, Chun, Xu, Lu, Chugh, Rashmi, Tolcher, Anthony, Goldman, Jonathan, Dupont, Jakob, Brachmann, Raiiner K., Papadopoulos, Kyriakos, Kapoun, Ann M.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A107: In vivo screen of regorafenib in a panel of low passage START-PDX colorectal models: Working to identify a sensitive patient subpopulation

Abstract A107: In vivo screen of regorafenib in a panel of low passage START-PDX colorectal models: Working to identify a sensitive patient subpopulation

by Wick, Michael J., Gamez, Lizette, Diaz, Armando, Vaught, Teresa L., Tolcher, Anthony W., Rasco, Drew, Patnaik, Amita, Smith, Lon, Drengler, Ron, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A13: Establishment and characterization of a panel of melanoma patient-derived xenograft (PDX) models

Abstract A13: Establishment and characterization of a panel of melanoma patient-derived xenograft (PDX) models

by Gamez, Lizette, Wick, Michael J., Vaught, Teresa L., Farley, Monica, Tolcher, Anthony W., Rasco, Drew, Patnaik, Amita, Miller, Alex, Drengler, Ron, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract C104: Preclinical sensitivity of low and high-HER2 expressing START-PDX breast models to T-DM1 and effects of HER3 expression on drug antitumor activity

Abstract C104: Preclinical sensitivity of low and high-HER2 expressing START-PDX breast models to T-DM1 and effects of HER3 expression on drug antitumor activity

by Wick, Michael J., Brown, Jennifer, Vaught, Teresa L., Meade, Justin, Tolcher, Anthony W., Rasco, Drew, Patnaik, Amita, Lang, Amy, Beeram, Murali, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract A105: Establishment, characterization and clinical correlation of a panel of gynecologic patient-derived xenograft (PDX) models

Abstract A105: Establishment, characterization and clinical correlation of a panel of gynecologic patient-derived xenograft (PDX) models

by Wick, Michael J., Felder, Abbey, Moriarty, Alyssa, Vaught, Teresa L., Tolcher, Anthony W., Rasco, Drew, Patnaik, Amita, White, Allen J., Mark, James, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

Abstract C10: Establishment and characterization of melanoma patient-derived xenograft (PDX) model sets: correlation with clinical response and progression using serial biopsy sampling

Abstract C10: Establishment and characterization of melanoma patient-derived xenograft (PDX) model sets: correlation with clinical response and progression using serial biopsy sampling

by Wick, Michael J., Meade, Justin, Brown, Jennifer, Vaught, Teresa L., Tolcher, Anthony W., Gamez, Lizette, Rasco, Drew, Patnaik, Amita, Drengler, Ronald, Papadopoulos, Kyriakos P.
Published in Molecular cancer therapeutics (01.11.2013)

Get full text

Journal Article

[1]
Prev
10
11
12
13
14
15
16
17
18
19
20
Next
[20]